Trexquant Investment LP Has $629,000 Stock Holdings in biote Corp. (NASDAQ:BTMD)

Trexquant Investment LP boosted its position in shares of biote Corp. (NASDAQ:BTMD - Free Report) by 423.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 101,757 shares of the company's stock after buying an additional 82,303 shares during the quarter. Trexquant Investment LP owned approximately 0.19% of biote worth $629,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in BTMD. Commonwealth Equity Services LLC acquired a new stake in biote in the fourth quarter worth about $68,000. Intech Investment Management LLC acquired a new position in biote in the fourth quarter valued at approximately $71,000. SG Americas Securities LLC bought a new position in biote in the fourth quarter valued at approximately $76,000. Thompson Davis & CO. Inc. bought a new stake in shares of biote during the 4th quarter valued at $77,000. Finally, Jane Street Group LLC lifted its stake in shares of biote by 24.7% in the 3rd quarter. Jane Street Group LLC now owns 16,873 shares of the company's stock valued at $94,000 after purchasing an additional 3,342 shares during the period. 21.68% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other biote news, major shareholder Guines Llc bought 750,000 shares of biote stock in a transaction that occurred on Thursday, March 13th. The stock was acquired at an average price of $3.22 per share, for a total transaction of $2,415,000.00. Following the completion of the acquisition, the insider now owns 3,820,938 shares of the company's stock, valued at $12,303,420.36. This trade represents a 24.42 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Stephen Mark Cone purchased 38,104 shares of the stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $3.88 per share, for a total transaction of $147,843.52. Following the completion of the purchase, the director now directly owns 160,829 shares in the company, valued at approximately $624,016.52. The trade was a 31.05 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 958,435 shares of company stock worth $3,118,936 over the last three months. Corporate insiders own 24.00% of the company's stock.

biote Stock Down 0.9 %

NASDAQ BTMD traded down $0.03 during trading on Thursday, reaching $3.28. 29,123 shares of the stock traded hands, compared to its average volume of 185,524. The stock's 50-day moving average price is $3.98 and its 200 day moving average price is $5.15. The firm has a market cap of $179.45 million, a price-to-earnings ratio of 12.62 and a beta of 1.17. biote Corp. has a fifty-two week low of $3.04 and a fifty-two week high of $8.44.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum cut their target price on biote from $12.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday, March 13th.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.